- Gilead Sciences (NASDAQ:GILD) and WuXi PharmaTech (NYSE:WX) establish a strategic partnership to conduct analytical and stability studies of small molecule new chemical entities to support global marketing applications and commercial products.
- Specifically, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square foot analytical testing facility in Shanghai that will provide analytical and stability testing services including analytical method development, transfer and validation for regulatory submissions, commercial API (active pharmaceutical ingredient) and drug product testing, stability studies of APIs, drug products for registration, and reference standard qualification.
- Financial terms are not disclosed.